| pubmed-article:12113075 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12113075 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:12113075 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:12113075 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:12113075 | lifeskim:mentions | umls-concept:C0439640 | lld:lifeskim |
| pubmed-article:12113075 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:12113075 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:12113075 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:12113075 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12113075 | pubmed:dateCreated | 2002-7-12 | lld:pubmed |
| pubmed-article:12113075 | pubmed:abstractText | Identification of tumor-specific target antigens has been a major hurdle for the treatment of malignant disease by vaccination or immunotherapy. A second challenge has been the induction of therapeutically effective immune responses to these 'self' antigens. The recent recognition of dendritic cells as powerful antigen-presenting cells capable of inducing primary T-cell responses in vitro and in vivo--in combination with identification of tumor-specific antigens--has generated widespread interest in dendritic cell-based immunotherapy against a wide variety of tumors. In this review, a series of recently identified novel ovarian tumor antigens is discussed, and the potential for therapeutic dendritic cell vaccination targeted against these antigens is assessed. | lld:pubmed |
| pubmed-article:12113075 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12113075 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12113075 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12113075 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12113075 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12113075 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:12113075 | pubmed:issn | 1473-7140 | lld:pubmed |
| pubmed-article:12113075 | pubmed:author | pubmed-author:SantinAlessan... | lld:pubmed |
| pubmed-article:12113075 | pubmed:author | pubmed-author:CannonMartin... | lld:pubmed |
| pubmed-article:12113075 | pubmed:author | pubmed-author:O'BrienTimoth... | lld:pubmed |
| pubmed-article:12113075 | pubmed:author | pubmed-author:UnderwoodL... | lld:pubmed |
| pubmed-article:12113075 | pubmed:author | pubmed-author:CrewMark DMD | lld:pubmed |
| pubmed-article:12113075 | pubmed:author | pubmed-author:BondurantKris... | lld:pubmed |
| pubmed-article:12113075 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12113075 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:12113075 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12113075 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12113075 | pubmed:pagination | 97-105 | lld:pubmed |
| pubmed-article:12113075 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:meshHeading | pubmed-meshheading:12113075... | lld:pubmed |
| pubmed-article:12113075 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12113075 | pubmed:articleTitle | Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer. | lld:pubmed |
| pubmed-article:12113075 | pubmed:affiliation | Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA. cannonmartin@uams.edu | lld:pubmed |
| pubmed-article:12113075 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12113075 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12113075 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12113075 | lld:pubmed |
